BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26867317)

  • 1. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
    Zhang ZQ; Zhong CL; Zhao X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
    Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
    Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
    Peng ZH; Kopeček J
    J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
    Deng Z; Xiao Y; Pan M; Li F; Duan W; Meng L; Liu X; Yan F; Zheng H
    J Control Release; 2016 Dec; 243():333-341. PubMed ID: 27984104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity.
    Wang W; Shao A; Zhang N; Fang J; Ruan JJ; Ruan BH
    Sci Rep; 2017 Feb; 7():43036. PubMed ID: 28225062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].
    Gao B; Mu W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 39(8):769-74. PubMed ID: 25202944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
    Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
    Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.
    Biswas S; Dodwadkar NS; Deshpande PP; Parab S; Torchilin VP
    Eur J Pharm Biopharm; 2013 Aug; 84(3):517-25. PubMed ID: 23333899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
    Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
    ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targetable drug delivery system based on cell membrane camouflaged liposome for enhanced tumor targeting and improved anti-tumor efficiency.
    Duan M; Zhou D; Ke J; Chen Y; Wu W; Li Y; Ren J; Wang L; Zhang Z; Wang C
    Colloids Surf B Biointerfaces; 2024 Jun; 238():113892. PubMed ID: 38581834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma.
    Deng C; Zhang Q; Fu Y; Sun X; Gong T; Zhang Z
    ACS Appl Mater Interfaces; 2017 Jan; 9(2):1280-1292. PubMed ID: 28009503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iNGR-Modified Liposomes for Tumor Vascular Targeting and Tumor Tissue Penetrating Delivery in the Treatment of Glioblastoma.
    Zhou JE; Yu J; Gao L; Sun L; Peng T; Wang J; Zhu J; Lu W; Zhang L; Yan Z; Yu L
    Mol Pharm; 2017 May; 14(5):1811-1820. PubMed ID: 28388081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.